Contact

Roche : Leading Pharmaceutical Company in Health Diagnostics


, ,
Integral service around a transaction
BY : Diego GutiérrezMarch Thu, 2020

RocheRoche, the Swiss multinational pharmaceuticals company, has become a leader among companies in the relatively new and fast-growing Health Diagnostics sector. In terms of investment, Roche through Roche Venture Fundis one of the most active companies in the sector, having made 85 investments and 20 exits to date. Its latest investment, announced on 10 January 2020, was in the company Aligos Therapeutics.

The "Health Diagnostics" sector includes all companies dedicated to the development of techniques and instruments that facilitate the early diagnosis of pathologies and/or diseases and enable action to be taken against them as soon as possible. As already mentioned in previous posts published, technological progress, the application of artificial intelligence in medicine and the rise of biotechnology have enabled strong growth in this sector in recent years, and although it could be said that it is a relatively new market, there are certain companies, such as Roche, that have managed to stand out and grow above the rest.

 

THE COMPANY

Roche AG is a multinational healthcare company operating globally under two divisions: Pharmaceuticals and Diagnostics. It is headquartered in Basel, Switzerland.

Today, it is the leading pharmaceutical company in the market, with a turnover of almost €50 billion and a net profit of €9.5 billion in 2018. In addition, it increased its turnover by 7% and profit by 23% over the previous year.

It is listed on the SIX Swiss Exchange, Switzerland's leading stock exchange.

La Roche

INVESTMENTS MADE BY ROCHE

One of Roche's most recent investments has been in Spanish startup Minoryx Therapeutics, which has closed a €21.3 million Series B round of Early Stage financing with a minority stake. Minoryx is an innovative company dedicated to the research and development of treatments for genetic diseases affecting the central nervous system. Roche had already participated in Minoryx's Early Stage Series A financing round in 2015.

In 2017, it also invested in another Series A round of Early Stage funding, this time in French biotech startup Vivet Therapeutics. This round had a total amount of 37.5 million euros, the investment was led jointly by Novartis Venture Fund and Columbus Venture Partners, with Roche taking a minority stake.

▶You may be interested in: Health diagnostics: Key investors at each stage

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu